♪♪ >>> TONIGHT, A BRUTAL MARCH MEGASTORM RIPPING ACROSS THE COUNTRY. DAMAGING WINDS AND INTENSE RAIN BATTERING THE EAST WHILE THE MIDWEST DIGS OUT FROM RECORD-BREAKING SNOW. LOOK AT THE WHITEOUT CONDITIONS, BLIZZARDS MAKING THE ROADS MESSY DAYS BEFORE SPRING.FIREFIGHTERS TRY TO GET A HANDLE ON THIS WAREHOUSE FIRE IN THE BITTER COLD. DRAMATIC COAST GUARD RESCUE OF A SNOWMOBILER ON A ICE SHELF. ON THE EAST COAST, RARE TORNADO WATCHES, WITH PUNISHING WINDS DOING DAMAGE FROM CHARLOTTE TO THE NATION'S CAPITAL, A ...

In tonight, President Trump revealing his chief of staff, one of the most powerful people in Washington, has been diagnosed with breast cancer. Kelly O'Donnell is here with us tonight. And Kelly, Susie Wilds is going to go through treatment while basically working full-time like many women do.And good to be with you, Hie. Susie Wilds holds a special kind of authority in Washington. She has the president's trust and carries considerable influence as the first woman to ever serve as White House chief of staff ...

PETER, APART FROM THE WAR, WE JUST GOT A STATEMENT FROM T PRESIDENT VIA TRUTH SOCIAL ABOUT his chief of staff and I'm just going to read it in its entirety. Susie Wiles is an incredible chief of staff, a great person and one of the strongest people I know but unfortunately she has been diagnosed with early stage breast cancer and has decided to DECIDED TO TAKE ON THIS CHALLENGE IMMEDIATELY, AS OPPOSED TO WAITING. SHE HAS A FANTASTIC MEDICAL TEAM AND HER PROGNOSIS IS EXCELLENT.DURING THE TREATMENT PERIOD, SH ...

President Trump said White House chief of staff Susie Wiles has been diagnosed with early-stage breast cancer and will undergo treatment https://t.co/aovrL5PoQb ...

Breast cancer is the most diagnosed cancer among women globally, and the number of cases worldwide is estimated to reach over 3.5 million by 2050, new research has found. https://t.co/ian8t8yUiB https://t.co/FONO2IuJNu ...

Summary of Relay Therapeutics FY Conference Call Company Overview - **Company**: Relay Therapeutics (NasdaqGM: RLAY) - **Key Speakers**: Sanjiv Patel (President and CEO), Peter Rahmer (Chief Corporate Development Officer), Don Bergstrom (President of R&D) Core Industry Focus - **Primary Areas of Focus**: - Vascular malformations - Breast cancer - **Key Product**: Zovegalisib, a PI3K mutant selective molecule Key Points and Arguments Financial and Strategic Positioning - Relay Therapeutics has made deliberate choices to focus capital on advancing zovegalisib, extending cash runway into 2029 [2][3] - The company outlicensed its most advanced clinical program, lirafugratinib, to concentrate on three large clinical areas: - 2nd line hormone receptor-positive, HER2-negative breast cancer - 1st line metastatic hormone receptor HER2-negative breast cancer - PI3K driven vascular anomalies [2][3] Clinical Data and Upcoming Disclosures - Upcoming data disclosures include: - 2nd-line metastatic breast cancer data at ESMO TAT in Paris [3] - Data from 57 patients on a 400 mg BID fed dose, expected to show consistency with previous data [4] - Vascular anomalies data from 20 patients at the 12-week efficacy endpoint [5][6] Vascular Malformations Insights - Vascular malformations are driven by PI3K mutations, with previous proof of concept from non-selective PI3K inhibitors [9] - The company aims to show meaningful differentiation in response rates for zovegalisib compared to existing treatments [9][10] - There are approximately 170,000 PIK3CA-driven vascular anomaly patients in the U.S., with about 100,000 in the three subtypes of interest [15][16] - The company estimates that 25,000 of these patients would seek chronic systemic therapy [17] Trial Design and Regulatory Considerations - The ReInspire trial is designed to evaluate zovegalisib across three different dose levels, with a focus on safety and tolerability [20][21] - The primary endpoint for potential accelerated approval is the objective response rate (ORR), with a target of a 20% reduction in lesion volume [25] - The company aims to exceed the response rates of existing treatments, which range from 11% to 27% [25] Safety and Tolerability - Safety and tolerability are critical, as the treatment will be chronic, starting in childhood [26][28] - The company is focused on achieving a favorable risk-benefit profile to support long-term treatment decisions [26][28] Competitive Landscape - Zovegalisib is positioned against other treatments like alpelisib and sirolimus, with a focus on differentiating its patient population and treatment approach [30][32] - The company believes that the patient populations for zovegalisib and competing treatments will not significantly overlap [30][32] Breast Cancer Developments - The company is also advancing its breast cancer programs, with plans to share data on combination therapies and trial designs [41][50] - The focus is on ensuring tolerability in long-term treatment regimens, particularly in combination with CDK4/6 inhibitors [43][55] Additional Important Insights - The company is actively enrolling patients globally in its trials and is optimistic about the progress made so far [50] - There is ongoing interest in exploring combinations with SIRD agents in the future [61] This summary encapsulates the key points discussed during the Relay Therapeutics FY Conference Call, highlighting the company's strategic focus, clinical developments, and competitive positioning in the biotech industry.

Having breast cancer in your 20s or 30s brings a unique set of considerations – and agonies https://t.co/2aonu7VkJo ...

Core Message - The "gap," representing challenging or unexpected situations, is presented as a valuable opportunity for growth and development, not just a setback [5][9][18] - Embracing the gap leads to the development of grit, the formation of alliances, and the gaining of perspective, all crucial for success [10][12][15] Entrepreneurial Insights - Success in entrepreneurship requires more than just endurance; it necessitates a mindset shift to recognize the value within challenging situations [9] - Entrepreneurs are often hesitant to seek help, but the "gap" highlights the necessity of collaboration and building a strong network of allies [13] - Teams that embrace clarity and flexible decision-making outperform their peers by 30% [16] Failure and Growth - Failure is an inherent part of the "gap," and the way it is perceived determines future success; it can be either a finality or fuel for growth [19][20] - Startups often fail due to gaps in leadership, collaboration, and perspective, rather than product flaws; CB Insights indicates a 70% failure rate [17] Personal Development - The "gap" is a universal experience, not limited to entrepreneurs, and can manifest in various forms, such as professional setbacks or personal challenges [19] - Embracing the "gap" and allowing it to shape one's path is essential for personal growth and achieving one's potential [23][24]

Having breast cancer in your 20s or 30s brings a unique set of considerations – and agonies https://t.co/YTe9TFFMDH ...

Hormone Replacement Therapy (HRT) Safety and Efficacy - The FDA Commissioner suggests removing black box warnings from HRT products, arguing they have unnecessarily deterred women from using these treatments [1][12] - A 2002 study led to a nearly 50% reduction in HRT use due to concerns about increased risks of heart disease and breast cancer [2] - Subsequent clinical trials have not confirmed that HRT increases breast cancer mortality, and cardiovascular complications are linked to starting HRT more than 10 years after menopause onset [4] - Starting HRT within 10 years of menopause onset can reduce heart disease risk by 30-50% and heart attack deaths by 48% [5] Benefits of HRT - HRT can alleviate menopause symptoms, which 80% of women experience, including hot flashes, night sweats, mood swings, and weight gain [6][7] - Long-term benefits of HRT include reducing cognitive decline by up to 64% and Alzheimer's risk by 35% in some studies, as well as reducing bone fracture rates [7] Considerations for HRT Use - The 2002 study had flaws, including exclusively studying women who were on average 10 years post-menopause with an average age of 63, a demographic already vulnerable to cardiovascular disease [8] - The study only evaluated one delivery method (a daily pill combining estrogen and progesterone), while delivery methods have improved since then [9] - Contraindications for HRT include a predisposing risk to blood clots or active breast cancer, but these are rare [14] - Doctors generally don't prescribe hormone therapy if you're over age 60 or more than 10 years after the onset of menopause [18] - Estrogen reduces cardiovascular risk in post-menopausal women by 30 to 50% [21]